Combretastatin is on my watch list, but I am more concerned about Macugen and Lucentis. So let me turn this around and ask why you find Combretastatin such a compelling threat; i.e. why do you think it will be either safer or more effective than other anti-angio drug candidates?
BTW: if there is ever a head-to-head trial of Squalamine vs Combretastatin, the trial will be known as “Shark vs Bark.”
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.